Literature DB >> 8601418

Intracellular transactivation of the insulin-like growth factor I receptor by an epidermal growth factor receptor.

J L Burgaud1, R Baserga.   

Abstract

Growth factor receptors may be transactivated not only by homologous receptors, but also by heterologous receptors. We have investigated this possibility, using for this purpose R-/EGFR cells, which are mouse embryo cells devoid of IGF-I receptors, but overexpressing the EGF receptor. At variance with mouse embryo cells with a wild-type number of IGF-I receptors and overexpressing the EGF receptor, R-/EGFR cells cannot grow in EGF only, nor can they form colonies in soft agar. However, if a wild type human IGF-I receptor is stably transfected into R-/EGFR cells, growth in EGF and colony formation in soft agar are restored. To determine a possible interaction between the two receptors, we transfected into R-/EGFR cells a number of IGF-I receptor mutants with different impaired functions. The only IGF-I receptor that cannot reverse the growth phenotype of R-/EGFR cells is a receptor with a point mutation at the ATP-binding site. All other mutant receptors, even when incapable of responding to IGF-I with a mitogenic signal, made R-/EGFR cells fully capable of responding with growth to EGF stimulation. IGF-I receptor mutants that are mitogenic but not transforming made R-/EGFR cells grow in EGF only, but were incapable of inducing the transformed phenotype. The mutant IGF-I receptors are activated (tyrosyl phosphorylation of IRS-I) in response to EGF. These experiments indicate that certain IGF-I receptor mutants with loss of function can be reactivated intracellularly by an overexpressed EGF receptor and confirm that the C-terminus of the IGF-IR is required for its transforming activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8601418     DOI: 10.1006/excr.1996.0096

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  6 in total

Review 1.  Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.

Authors:  Michael Höpfner; Detlef Schuppan; Hans Scherübl
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

2.  Preparation of a recombinant chimaera of insulin-like growth factor II and interleukin 3 with high proliferative potency for haemopoietic cells.

Authors:  M R Difalco; L F Congote
Journal:  Biochem J       Date:  1997-09-01       Impact factor: 3.857

3.  Mystique is a new insulin-like growth factor-I-regulated PDZ-LIM domain protein that promotes cell attachment and migration and suppresses Anchorage-independent growth.

Authors:  Gary Loughran; Nollaig C Healy; Patrick A Kiely; Merei Huigsloot; Nancy L Kedersha; Rosemary O'Connor
Journal:  Mol Biol Cell       Date:  2005-01-19       Impact factor: 4.138

4.  Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation.

Authors:  Y Saito; J Haendeler; Y Hojo; K Yamamoto; B C Berk
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

Review 5.  Role of insulin-like growth factor I signaling in neurodegenerative diseases.

Authors:  José Luis Trejo; Eva Carro; Eva Garcia-Galloway; Ignacio Torres-Aleman
Journal:  J Mol Med (Berl)       Date:  2003-11-28       Impact factor: 4.599

6.  Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention.

Authors:  Doris M Benbrook; Stan Lightfoot; James Ranger-Moore; Tongzu Liu; Shylet Chengedza; William L Berry; Igor Dozmorov
Journal:  Gene Regul Syst Bio       Date:  2008
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.